{"transactions":[{"id":4623642,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-21T21:45:30.000Z","date":"2026-09-18","kind":"grant","planned":false,"acquired":true,"shares":7707,"price":1.93,"value":14874.51,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were issued in accordance with the Issuer's Sixth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on September 17, 2026."}],"balance_after":110236,"source":{"system":"sec-edgar","filing":"0001193125-26-396868","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000119312526396868/ownership.xml","form_type":"4"}},{"id":4623620,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":34820,"kind":"person","name":"Raman Prakash","position":1,"cik":"0002018686","reported_name":"Raman Prakash","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-21T21:30:27.000Z","date":"2026-09-18","kind":"grant","planned":false,"acquired":true,"shares":6801,"price":1.93,"value":13125.93,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were issued in accordance with the Issuer's Sixth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on September 17, 2026."}],"balance_after":51840,"source":{"system":"sec-edgar","filing":"0002018686-26-000014","document":"form4-09212026_090921.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2018686/000201868626000014/form4-09212026_090921.xml","form_type":"4"}},{"id":723995,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-29T20:40:15.000Z","date":"2026-06-26","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 26, 2027 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":40000,"derivative":{"exercise_price":1.71,"expiration_date":"2036-06-25","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001193125-26-288598","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000119312526288598/ownership.xml","form_type":"4"}},{"id":723994,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":34821,"kind":"person","name":"Kulkarni Samarth","position":1,"cik":"0001682019","reported_name":"Kulkarni Samarth","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-29T20:37:58.000Z","date":"2026-06-26","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 26, 2027 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":40000,"derivative":{"exercise_price":1.71,"expiration_date":"2036-06-25","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001682019-26-000002","document":"form4-06292026_080654.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000168201926000002/form4-06292026_080654.xml","form_type":"4"}},{"id":723992,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":34819,"kind":"person","name":"Menzel Garry E","position":1,"cik":"0001556064","reported_name":"Menzel Garry E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-29T20:37:15.000Z","date":"2026-06-26","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 26, 2027 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":40000,"derivative":{"exercise_price":1.71,"expiration_date":"2036-06-25","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001556064-26-000002","document":"form4-06292026_080611.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000155606426000002/form4-06292026_080611.xml","form_type":"4"}},{"id":723993,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":34820,"kind":"person","name":"Raman Prakash","position":1,"cik":"0002018686","reported_name":"Raman Prakash","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-29T20:36:15.000Z","date":"2026-06-26","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 26, 2027 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":40000,"derivative":{"exercise_price":1.71,"expiration_date":"2036-06-25","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0002018686-26-000012","document":"form4-06292026_080611.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000201868626000012/form4-06292026_080611.xml","form_type":"4"}},{"id":723991,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":34818,"kind":"person","name":"Dhingra Kapil","position":1,"cik":"0001456849","reported_name":"Dhingra Kapil","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-29T20:34:03.000Z","date":"2026-06-26","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 26, 2027 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":40000,"derivative":{"exercise_price":1.71,"expiration_date":"2036-06-25","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001456849-26-000002","document":"form4-06292026_080659.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000145684926000002/form4-06292026_080659.xml","form_type":"4"}},{"id":723990,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":34817,"kind":"person","name":"Campbell Shannon","position":1,"cik":"0002018966","reported_name":"Campbell Shannon","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-29T20:32:56.000Z","date":"2026-06-26","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 26, 2027 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":40000,"derivative":{"exercise_price":1.71,"expiration_date":"2036-06-25","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0002018966-26-000007","document":"form4-06292026_080653.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000201896626000007/form4-06292026_080653.xml","form_type":"4"}},{"id":730511,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-22T20:19:12.000Z","date":"2026-06-19","kind":"grant","planned":false,"acquired":true,"shares":8961,"price":1.66,"value":14875.26,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were issued in accordance with the Issuer's Sixth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on June 18, 2026."}],"balance_after":102529,"source":{"system":"sec-edgar","filing":"0001193125-26-277553","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000119312526277553/ownership.xml","form_type":"4"}},{"id":730509,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":34820,"kind":"person","name":"Raman Prakash","position":1,"cik":"0002018686","reported_name":"Raman Prakash","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-22T20:06:03.000Z","date":"2026-06-19","kind":"grant","planned":false,"acquired":true,"shares":7907,"price":1.66,"value":13125.62,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were issued in accordance with the Issuer's Sixth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on June 18, 2026."}],"balance_after":45039,"source":{"system":"sec-edgar","filing":"0002018686-26-000008","document":"form4-06222026_080600.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000201868626000008/form4-06222026_080600.xml","form_type":"4"}},{"id":832331,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-03-20T21:27:25.000Z","date":"2026-03-20","kind":"grant","planned":false,"acquired":true,"shares":6919,"price":2.15,"value":14875.85,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were issued in accordance with the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on March 19, 2026."}],"balance_after":93568,"source":{"system":"sec-edgar","filing":"0001193125-26-117938","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000119312526117938/ownership.xml","form_type":"4"}},{"id":832330,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":34820,"kind":"person","name":"Raman Prakash","position":1,"cik":"0002018686","reported_name":"Raman Prakash","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-03-20T21:19:05.000Z","date":"2026-03-20","kind":"grant","planned":false,"acquired":true,"shares":6105,"price":2.15,"value":13125.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were issued in accordance with the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on March 19, 2026."}],"balance_after":37132,"source":{"system":"sec-edgar","filing":"0002018686-26-000002","document":"form4-03202026_090300.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000201868626000002/form4-03202026_090300.xml","form_type":"4"}},{"id":932310,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":68908,"kind":"person","name":"Hatzis-Schoch Brent","position":1,"cik":"0001637054","reported_name":"Hatzis-Schoch Brent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SEE REMARKS"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-23T21:05:12.000Z","date":"2026-01-21","kind":"grant","planned":false,"acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to this option shall vest and become exercisable on January 21, 2027, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":250000,"derivative":{"exercise_price":2.57,"expiration_date":"2036-01-20","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001637054-26-000002","document":"form4-01232026_040109.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000163705426000002/form4-01232026_040109.xml","form_type":"4"}},{"id":932309,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":68907,"kind":"person","name":"Yurasov Sergey","position":1,"cik":"0001686295","reported_name":"Yurasov Sergey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-23T21:05:08.000Z","date":"2026-01-21","kind":"grant","planned":false,"acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to this option shall vest and become exercisable on January 21, 2027, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":250000,"derivative":{"exercise_price":2.57,"expiration_date":"2036-01-20","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001686295-26-000002","document":"form4-01232026_040104.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000168629526000002/form4-01232026_040104.xml","form_type":"4"}},{"id":932308,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-23T21:05:05.000Z","date":"2026-01-21","kind":"grant","planned":false,"acquired":true,"shares":600000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to this option shall vest and become exercisable on January 21, 2027, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":600000,"derivative":{"exercise_price":2.57,"expiration_date":"2036-01-20","underlying":"Common Stock","underlying_shares":600000},"source":{"system":"sec-edgar","filing":"0001706847-26-000002","document":"form4-01232026_040101.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000170684726000002/form4-01232026_040101.xml","form_type":"4"}},{"id":932720,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":68944,"kind":"person","name":"Jones Erika","position":1,"cik":"0001895913","reported_name":"Jones Erika","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SEE REMARKS"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-23T16:05:14.000Z","date":"2026-01-21","kind":"grant","planned":false,"acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to this option shall vest and become exercisable on January 21, 2027, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":200000,"derivative":{"exercise_price":2.57,"expiration_date":"2036-01-20","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001895913-26-000002","document":"form4-01232026_040111.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1895913/000189591326000002/form4-01232026_040111.xml","form_type":"4"}},{"id":932464,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":68914,"kind":"person","name":"Buck Elizabeth","position":1,"cik":"0001880385","reported_name":"Buck Elizabeth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF SCIENTIFIC OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-23T16:05:11.000Z","date":"2026-01-21","kind":"grant","planned":false,"acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to this option shall vest and become exercisable on January 21, 2027, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":250000,"derivative":{"exercise_price":2.57,"expiration_date":"2036-01-20","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001880385-26-000002","document":"form4-01232026_040106.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880385/000188038526000002/form4-01232026_040106.xml","form_type":"4"}},{"id":969505,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-15T21:39:20.000Z","date":"2025-12-12","kind":"grant","planned":false,"acquired":true,"shares":5208,"price":2.76,"value":14374.08,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were issued in accordance with the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on December 11, 2025."}],"balance_after":86649,"source":{"system":"sec-edgar","filing":"0001193125-25-319303","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000119312525319303/ownership.xml","form_type":"4"}},{"id":969502,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":34820,"kind":"person","name":"Raman Prakash","position":1,"cik":"0002018686","reported_name":"Raman Prakash","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-15T21:33:14.000Z","date":"2025-12-12","kind":"grant","planned":false,"acquired":true,"shares":4665,"price":2.76,"value":12875.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were issued in accordance with the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on December 11, 2025."}],"balance_after":31027,"source":{"system":"sec-edgar","filing":"0002018686-25-000007","document":"form4-12152025_091210.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000201868625000007/form4-12152025_091210.xml","form_type":"4"}},{"id":1034594,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-09-22T21:58:01.000Z","date":"2025-09-19","kind":"grant","planned":false,"acquired":true,"shares":4291,"price":3.35,"value":14374.85,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were issued in accordance with the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on September 18, 2025."}],"balance_after":81441,"source":{"system":"sec-edgar","filing":"0001193125-25-211678","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000119312525211678/ownership.xml","form_type":"4"}},{"id":1034595,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":34820,"kind":"person","name":"Raman Prakash","position":1,"cik":"0002018686","reported_name":"Raman Prakash","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-09-22T21:45:37.000Z","date":"2025-09-19","kind":"grant","planned":false,"acquired":true,"shares":3843,"price":3.35,"value":12874.05,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were issued in accordance with the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on September 18, 2025."}],"balance_after":26362,"source":{"system":"sec-edgar","filing":"0002018686-25-000004","document":"form4-09222025_090933.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000201868625000004/form4-09222025_090933.xml","form_type":"4"}},{"id":1105040,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-20T20:21:52.000Z","date":"2025-06-20","kind":"grant","planned":false,"acquired":true,"shares":6170,"price":2.33,"value":14376.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were issued in accordance with the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on June 18, 2025."}],"balance_after":77150,"source":{"system":"sec-edgar","filing":"0000950170-25-088527","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000095017025088527/ownership.xml","form_type":"4"}},{"id":1105039,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":34820,"kind":"person","name":"Raman Prakash","position":1,"cik":"0002018686","reported_name":"Raman Prakash","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-20T20:12:52.000Z","date":"2025-06-20","kind":"grant","planned":false,"acquired":true,"shares":5526,"price":2.33,"value":12875.58,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were issued in accordance with the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on June 18, 2025."}],"balance_after":22519,"source":{"system":"sec-edgar","filing":"0001415889-25-017821","document":"form4-06202025_080647.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000141588925017821/form4-06202025_080647.xml","form_type":"4"}},{"id":1113458,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-12T22:34:31.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":30550,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 12, 2026 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":30550,"derivative":{"exercise_price":2.43,"expiration_date":"2035-06-11","underlying":"Common Stock","underlying_shares":30550},"source":{"system":"sec-edgar","filing":"0000950170-25-085676","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000095017025085676/ownership.xml","form_type":"4"}},{"id":1113457,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":34819,"kind":"person","name":"Menzel Garry E","position":1,"cik":"0001556064","reported_name":"Menzel Garry E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-12T22:26:40.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":30550,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 12, 2026 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":30550,"derivative":{"exercise_price":2.43,"expiration_date":"2035-06-11","underlying":"Common Stock","underlying_shares":30550},"source":{"system":"sec-edgar","filing":"0001415889-25-017058","document":"form4-06122025_100637.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000141588925017058/form4-06122025_100637.xml","form_type":"4"}},{"id":1113456,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":34820,"kind":"person","name":"Raman Prakash","position":1,"cik":"0002018686","reported_name":"Raman Prakash","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-12T22:25:56.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":30550,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 12, 2026 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":30550,"derivative":{"exercise_price":2.43,"expiration_date":"2035-06-11","underlying":"Common Stock","underlying_shares":30550},"source":{"system":"sec-edgar","filing":"0001415889-25-017056","document":"form4-06122025_100652.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000141588925017056/form4-06122025_100652.xml","form_type":"4"}},{"id":1113455,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":34817,"kind":"person","name":"Campbell Shannon","position":1,"cik":"0002018966","reported_name":"Campbell Shannon","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-12T22:24:33.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":30550,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 12, 2026 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":30550,"derivative":{"exercise_price":2.43,"expiration_date":"2035-06-11","underlying":"Common Stock","underlying_shares":30550},"source":{"system":"sec-edgar","filing":"0001415889-25-017053","document":"form4-06122025_100629.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000141588925017053/form4-06122025_100629.xml","form_type":"4"}},{"id":1113454,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":34818,"kind":"person","name":"Dhingra Kapil","position":1,"cik":"0001456849","reported_name":"Dhingra Kapil","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-12T22:23:13.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":30550,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 12, 2026 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":30550,"derivative":{"exercise_price":2.43,"expiration_date":"2035-06-11","underlying":"Common Stock","underlying_shares":30550},"source":{"system":"sec-edgar","filing":"0001415889-25-017050","document":"form4-06122025_100609.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000141588925017050/form4-06122025_100609.xml","form_type":"4"}},{"id":1113453,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":34821,"kind":"person","name":"Kulkarni Samarth","position":1,"cik":"0001682019","reported_name":"Kulkarni Samarth","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-12T22:22:19.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":30550,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 12, 2026 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":30550,"derivative":{"exercise_price":2.43,"expiration_date":"2035-06-11","underlying":"Common Stock","underlying_shares":30550},"source":{"system":"sec-edgar","filing":"0001415889-25-017048","document":"form4-06122025_100615.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000141588925017048/form4-06122025_100615.xml","form_type":"4"}},{"id":1194661,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-21T20:19:30.000Z","date":"2025-03-21","kind":"grant","planned":false,"acquired":true,"shares":7646,"price":1.88,"value":14374.48,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were issued in accordance with the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on March 20, 2025."}],"balance_after":70980,"source":{"system":"sec-edgar","filing":"0000950170-25-043221","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000095017025043221/ownership.xml","form_type":"4"}},{"id":1194660,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":34820,"kind":"person","name":"Raman Prakash","position":1,"cik":"0002018686","reported_name":"Raman Prakash","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-21T20:04:02.000Z","date":"2025-03-21","kind":"grant","planned":false,"acquired":true,"shares":6848,"price":1.88,"value":12874.24,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were issued in accordance with the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on March 20, 2025."}],"balance_after":16993,"source":{"system":"sec-edgar","filing":"0001415889-25-008771","document":"form4-03212025_080359.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000141588925008771/form4-03212025_080359.xml","form_type":"4"}},{"id":1196209,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":81732,"kind":"person","name":"BIOTECH GROWTH N V","position":1,"cik":"0001259869","reported_name":"BIOTECH GROWTH N V","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":81733,"kind":"organization","name":"BB BIOTECH AG","position":2,"cik":"0000924223","reported_name":"BB BIOTECH AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-03-21T01:01:40.000Z","date":"2025-03-19","kind":"sale","planned":false,"acquired":false,"shares":500000,"price":2.1169,"value":1058450.0,"ownership":{"direct":true},"balance_after":2733547,"source":{"system":"sec-edgar","filing":"0001104659-25-026305","document":"tm259930-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/924223/000110465925026305/tm259930-1_4seq1.xml","form_type":"4"}},{"id":1196208,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":81732,"kind":"person","name":"BIOTECH GROWTH N V","position":1,"cik":"0001259869","reported_name":"BIOTECH GROWTH N V","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":81733,"kind":"organization","name":"BB BIOTECH AG","position":2,"cik":"0000924223","reported_name":"BB BIOTECH AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-03-21T01:01:40.000Z","date":"2025-03-19","kind":"sale","planned":false,"acquired":false,"shares":584292,"price":1.9532,"value":1141239.1344,"ownership":{"direct":true},"balance_after":3233547,"source":{"system":"sec-edgar","filing":"0001104659-25-026305","document":"tm259930-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/924223/000110465925026305/tm259930-1_4seq1.xml","form_type":"4"}},{"id":1196207,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":81732,"kind":"person","name":"BIOTECH GROWTH N V","position":1,"cik":"0001259869","reported_name":"BIOTECH GROWTH N V","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":81733,"kind":"organization","name":"BB BIOTECH AG","position":2,"cik":"0000924223","reported_name":"BB BIOTECH AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-03-21T01:01:40.000Z","date":"2025-03-19","kind":"sale","planned":false,"acquired":false,"shares":400000,"price":2.0929,"value":837160.0,"ownership":{"direct":true},"balance_after":3817839,"source":{"system":"sec-edgar","filing":"0001104659-25-026305","document":"tm259930-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/924223/000110465925026305/tm259930-1_4seq1.xml","form_type":"4"}},{"id":1196206,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":81732,"kind":"person","name":"BIOTECH GROWTH N V","position":1,"cik":"0001259869","reported_name":"BIOTECH GROWTH N V","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":81733,"kind":"organization","name":"BB BIOTECH AG","position":2,"cik":"0000924223","reported_name":"BB BIOTECH AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-03-21T01:01:40.000Z","date":"2025-03-19","kind":"sale","planned":false,"acquired":false,"shares":2000000,"price":2.0004,"value":4000800.0,"ownership":{"direct":true},"balance_after":4217839,"source":{"system":"sec-edgar","filing":"0001104659-25-026305","document":"tm259930-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/924223/000110465925026305/tm259930-1_4seq1.xml","form_type":"4"}},{"id":1196205,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":81732,"kind":"person","name":"BIOTECH GROWTH N V","position":1,"cik":"0001259869","reported_name":"BIOTECH GROWTH N V","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":81733,"kind":"organization","name":"BB BIOTECH AG","position":2,"cik":"0000924223","reported_name":"BB BIOTECH AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-03-21T01:01:40.000Z","date":"2025-03-19","kind":"sale","planned":false,"acquired":false,"shares":1000000,"price":2.3081,"value":2308100.0,"ownership":{"direct":true},"balance_after":6217839,"source":{"system":"sec-edgar","filing":"0001104659-25-026305","document":"tm259930-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/924223/000110465925026305/tm259930-1_4seq1.xml","form_type":"4"}},{"id":1196204,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":81732,"kind":"person","name":"BIOTECH GROWTH N V","position":1,"cik":"0001259869","reported_name":"BIOTECH GROWTH N V","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":81733,"kind":"organization","name":"BB BIOTECH AG","position":2,"cik":"0000924223","reported_name":"BB BIOTECH AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-03-21T01:01:40.000Z","date":"2025-03-19","kind":"sale","planned":false,"acquired":false,"shares":300000,"price":1.943,"value":582900.0,"ownership":{"direct":true},"balance_after":7217839,"source":{"system":"sec-edgar","filing":"0001104659-25-026305","document":"tm259930-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/924223/000110465925026305/tm259930-1_4seq1.xml","form_type":"4"}},{"id":1196203,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":81732,"kind":"person","name":"BIOTECH GROWTH N V","position":1,"cik":"0001259869","reported_name":"BIOTECH GROWTH N V","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":81733,"kind":"organization","name":"BB BIOTECH AG","position":2,"cik":"0000924223","reported_name":"BB BIOTECH AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-03-21T01:01:40.000Z","date":"2025-03-19","kind":"sale","planned":false,"acquired":false,"shares":1000000,"price":2.0691,"value":2069100.0,"ownership":{"direct":true},"balance_after":7517839,"source":{"system":"sec-edgar","filing":"0001104659-25-026305","document":"tm259930-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/924223/000110465925026305/tm259930-1_4seq1.xml","form_type":"4"}},{"id":1289542,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-31T21:37:18.000Z","date":"2025-01-30","kind":"grant","planned":false,"acquired":true,"shares":500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to this option shall vest and become exercisable on January 30, 2026, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":500000,"derivative":{"exercise_price":2.52,"expiration_date":"2035-01-29","underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0001415889-25-002494","document":"form4-01312025_090114.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000141588925002494/form4-01312025_090114.xml","form_type":"4"}},{"id":1289541,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Common Stock","published_at":"2025-01-31T21:37:18.000Z","date":"2025-01-30","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a grant of Restricted Stock Units (\"RSUs\") under the Black Diamond Therapeutics, Inc. 2020 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: 50% of the RSUs shall vest on January 30, 2026 and the remaining 50% of the RSUs shall vest on January 30, 2027, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":121522,"source":{"system":"sec-edgar","filing":"0001415889-25-002494","document":"form4-01312025_090114.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000141588925002494/form4-01312025_090114.xml","form_type":"4"}},{"id":1289540,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":68907,"kind":"person","name":"Yurasov Sergey","position":1,"cik":"0001686295","reported_name":"Yurasov Sergey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-31T21:36:56.000Z","date":"2025-01-30","kind":"grant","planned":false,"acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to this option shall vest and become exercisable on January 30, 2026, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":200000,"derivative":{"exercise_price":2.52,"expiration_date":"2035-01-29","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001415889-25-002493","document":"form4-01312025_090152.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000141588925002493/form4-01312025_090152.xml","form_type":"4"}},{"id":1289539,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":68907,"kind":"person","name":"Yurasov Sergey","position":1,"cik":"0001686295","reported_name":"Yurasov Sergey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Common Stock","published_at":"2025-01-31T21:36:56.000Z","date":"2025-01-30","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a grant of Restricted Stock Units (\"RSUs\") under the Black Diamond Therapeutics, Inc. 2020 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: 50% of the RSUs shall vest on January 30, 2026 and the remaining 50% of the RSUs shall vest on January 30, 2027, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":75000,"source":{"system":"sec-edgar","filing":"0001415889-25-002493","document":"form4-01312025_090152.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000141588925002493/form4-01312025_090152.xml","form_type":"4"}},{"id":1289535,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":68908,"kind":"person","name":"Hatzis-Schoch Brent","position":1,"cik":"0001637054","reported_name":"Hatzis-Schoch Brent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SEE REMARKS"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-31T21:35:06.000Z","date":"2025-01-30","kind":"grant","planned":false,"acquired":true,"shares":175000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to this option shall vest and become exercisable on January 30, 2026, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":175000,"derivative":{"exercise_price":2.52,"expiration_date":"2035-01-29","underlying":"Common Stock","underlying_shares":175000},"source":{"system":"sec-edgar","filing":"0001415889-25-002486","document":"form4-01312025_090101.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000141588925002486/form4-01312025_090101.xml","form_type":"4"}},{"id":1289534,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":68908,"kind":"person","name":"Hatzis-Schoch Brent","position":1,"cik":"0001637054","reported_name":"Hatzis-Schoch Brent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SEE REMARKS"}}],"security":"Common Stock","published_at":"2025-01-31T21:35:06.000Z","date":"2025-01-30","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a grant of Restricted Stock Units (\"RSUs\") under the Black Diamond Therapeutics, Inc. 2020 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: 50% of the RSUs shall vest on January 30, 2026 and the remaining 50% of the RSUs shall vest on January 30, 2027, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":83400,"source":{"system":"sec-edgar","filing":"0001415889-25-002486","document":"form4-01312025_090101.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000141588925002486/form4-01312025_090101.xml","form_type":"4"}},{"id":1289695,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":68914,"kind":"person","name":"Buck Elizabeth","position":1,"cik":"0001880385","reported_name":"Buck Elizabeth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF SCIENTIFIC OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-31T16:36:26.000Z","date":"2025-01-30","kind":"grant","planned":false,"acquired":true,"shares":175000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to this option shall vest and become exercisable on January 30, 2026, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":175000,"derivative":{"exercise_price":2.52,"expiration_date":"2035-01-29","underlying":"Common Stock","underlying_shares":175000},"source":{"system":"sec-edgar","filing":"0001415889-25-002492","document":"form4-01312025_090123.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1880385/000141588925002492/form4-01312025_090123.xml","form_type":"4"}},{"id":1289694,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":68914,"kind":"person","name":"Buck Elizabeth","position":1,"cik":"0001880385","reported_name":"Buck Elizabeth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF SCIENTIFIC OFFICER"}}],"security":"Common Stock","published_at":"2025-01-31T16:36:26.000Z","date":"2025-01-30","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a grant of Restricted Stock Units (\"RSUs\") under the Black Diamond Therapeutics, Inc. 2020 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: 50% of the RSUs shall vest on January 30, 2026 and the remaining 50% of the RSUs shall vest on January 30, 2027, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":170192,"source":{"system":"sec-edgar","filing":"0001415889-25-002492","document":"form4-01312025_090123.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880385/000141588925002492/form4-01312025_090123.xml","form_type":"4"}},{"id":1290065,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":68944,"kind":"person","name":"Jones Erika","position":1,"cik":"0001895913","reported_name":"Jones Erika","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SEE REMARKS"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-31T16:35:46.000Z","date":"2025-01-30","kind":"grant","planned":false,"acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to this option shall vest and become exercisable on January 30, 2026, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":125000,"derivative":{"exercise_price":2.52,"expiration_date":"2035-01-29","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001415889-25-002489","document":"form4-01312025_090143.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1895913/000141588925002489/form4-01312025_090143.xml","form_type":"4"}},{"id":1290064,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":68944,"kind":"person","name":"Jones Erika","position":1,"cik":"0001895913","reported_name":"Jones Erika","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SEE REMARKS"}}],"security":"Common Stock","published_at":"2025-01-31T16:35:46.000Z","date":"2025-01-30","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a grant of Restricted Stock Units (\"RSUs\") under the Black Diamond Therapeutics, Inc. 2020 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: 50% of the RSUs shall vest on January 30, 2026 and the remaining 50% of the RSUs shall vest on January 30, 2027, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":85150,"source":{"system":"sec-edgar","filing":"0001415889-25-002489","document":"form4-01312025_090143.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1895913/000141588925002489/form4-01312025_090143.xml","form_type":"4"}},{"id":1330839,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-12-16T22:09:54.000Z","date":"2024-12-13","kind":"grant","planned":false,"acquired":true,"shares":5750,"price":2.5,"value":14375.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were issued in accordance with the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on December 12, 2024."}],"balance_after":63334,"source":{"system":"sec-edgar","filing":"0000950170-24-136739","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000095017024136739/ownership.xml","form_type":"4"}},{"id":1330838,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":34820,"kind":"person","name":"Raman Prakash","position":1,"cik":"0002018686","reported_name":"Raman Prakash","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-12-16T21:34:40.000Z","date":"2024-12-13","kind":"grant","planned":false,"acquired":true,"shares":5150,"price":2.5,"value":12875.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were issued in accordance with the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on December 12, 2024."}],"balance_after":10145,"source":{"system":"sec-edgar","filing":"0001415889-24-029482","document":"form4-12162024_091237.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000141588924029482/form4-12162024_091237.xml","form_type":"4"}},{"id":1330837,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":34817,"kind":"person","name":"Campbell Shannon","position":1,"cik":"0002018966","reported_name":"Campbell Shannon","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-12-16T21:34:15.000Z","date":"2024-12-13","kind":"grant","planned":false,"acquired":true,"shares":4500,"price":2.5,"value":11250.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were issued in accordance with the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on December 12, 2024."}],"balance_after":8865,"source":{"system":"sec-edgar","filing":"0001415889-24-029481","document":"form4-12162024_091212.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000141588924029481/form4-12162024_091212.xml","form_type":"4"}},{"id":1401619,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-20T20:30:56.000Z","date":"2024-09-20","kind":"grant","planned":false,"acquired":true,"shares":3007,"price":4.78,"value":14373.46,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were issued in accordance with the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on September 19, 2024."}],"balance_after":57584,"source":{"system":"sec-edgar","filing":"0000950170-24-108430","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000095017024108430/ownership.xml","form_type":"4"}},{"id":1401618,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":34817,"kind":"person","name":"Campbell Shannon","position":1,"cik":"0002018966","reported_name":"Campbell Shannon","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-20T20:24:43.000Z","date":"2024-09-20","kind":"grant","planned":false,"acquired":true,"shares":2354,"price":4.78,"value":11252.12,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were issued in accordance with the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on September 19, 2024."}],"balance_after":4365,"source":{"system":"sec-edgar","filing":"0001415889-24-023757","document":"form4-09202024_080939.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000141588924023757/form4-09202024_080939.xml","form_type":"4"}},{"id":1401617,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":34820,"kind":"person","name":"Raman Prakash","position":1,"cik":"0002018686","reported_name":"Raman Prakash","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-20T20:24:07.000Z","date":"2024-09-20","kind":"grant","planned":false,"acquired":true,"shares":2694,"price":4.78,"value":12877.32,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were issued in accordance with the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on September 19, 2024."}],"balance_after":4995,"source":{"system":"sec-edgar","filing":"0001415889-24-023755","document":"form4-09202024_080904.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000141588924023755/form4-09202024_080904.xml","form_type":"4"}},{"id":1419027,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":74643,"kind":"organization","name":"Versant Venture Capital VI, L.P.","position":1,"cik":"0001687880","reported_name":"Versant Venture Capital VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":87880,"kind":"organization","name":"Versant Voyageurs I, L.P.","position":2,"cik":"0001745960","reported_name":"Versant Voyageurs I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":87881,"kind":"organization","name":"Versant Voyageurs I Parallel, L.P.","position":3,"cik":"0001745961","reported_name":"Versant Voyageurs I Parallel, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":75031,"kind":"organization","name":"Versant Vantage I, L.P.","position":4,"cik":"0001765253","reported_name":"Versant Vantage I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-30T16:16:52.000Z","date":"2024-08-28","kind":"sale","planned":false,"acquired":false,"shares":221600,"price":6.3202,"value":1400556.32,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $6.32 to $6.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (1) to this Form 4."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held of record by Versant Venture Capital VI, L.P. (\"VVC VI\"). Versant Ventures VI GP, L.P. (\"VV VI GP\") is the general partner of VVC VI, and Versant Ventures VI GP-GP, LLC (\"VV VI GP-GP\") is the general partner of VV VI GP and each may be deemed to share voting, investment and dispositive power over the shares held by VVC VI. Each of VV VI GP-GP and VV VI GP disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein."}],"balance_after":3726341,"source":{"system":"sec-edgar","filing":"0000950170-24-102354","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1745960/000095017024102354/ownership.xml","form_type":"4"}},{"id":1472088,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-21T20:25:32.000Z","date":"2024-06-21","kind":"grant","planned":false,"acquired":true,"shares":2887,"price":4.98,"value":14377.26,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were issued in accordance with the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on June 20, 2024."}],"balance_after":54577,"source":{"system":"sec-edgar","filing":"0000950170-24-076273","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000095017024076273/ownership.xml","form_type":"4"}},{"id":1472089,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":34820,"kind":"person","name":"Raman Prakash","position":1,"cik":"0002018686","reported_name":"Raman Prakash","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-21T20:21:12.000Z","date":"2024-06-21","kind":"grant","planned":false,"acquired":true,"shares":2301,"price":4.98,"value":11458.98,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were issued in accordance with the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on June 20, 2024."}],"balance_after":2301,"source":{"system":"sec-edgar","filing":"0001415889-24-017843","document":"form4-06212024_080605.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000141588924017843/form4-06212024_080605.xml","form_type":"4"}},{"id":1472087,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":34817,"kind":"person","name":"Campbell Shannon","position":1,"cik":"0002018966","reported_name":"Campbell Shannon","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-21T20:20:35.000Z","date":"2024-06-21","kind":"grant","planned":false,"acquired":true,"shares":2011,"price":4.98,"value":10014.78,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were issued in accordance with the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on June 20, 2024."}],"balance_after":2011,"source":{"system":"sec-edgar","filing":"0001415889-24-017842","document":"form4-06212024_080631.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000141588924017842/form4-06212024_080631.xml","form_type":"4"}},{"id":1488475,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-06T22:20:41.000Z","date":"2024-06-06","kind":"grant","planned":false,"acquired":true,"shares":30550,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 6, 2025 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":30550,"derivative":{"exercise_price":4.65,"expiration_date":"2034-06-05","underlying":"Common Stock","underlying_shares":30550},"source":{"system":"sec-edgar","filing":"0000950170-24-070044","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000095017024070044/ownership.xml","form_type":"4"}},{"id":1488472,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":34821,"kind":"person","name":"Kulkarni Samarth","position":1,"cik":"0001682019","reported_name":"Kulkarni Samarth","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-06T21:55:15.000Z","date":"2024-06-06","kind":"grant","planned":false,"acquired":true,"shares":30550,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 6, 2025 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":30550,"derivative":{"exercise_price":4.65,"expiration_date":"2034-06-05","underlying":"Common Stock","underlying_shares":30550},"source":{"system":"sec-edgar","filing":"0001415889-24-015828","document":"form4-06062024_090611.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000141588924015828/form4-06062024_090611.xml","form_type":"4"}},{"id":1488469,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":34819,"kind":"person","name":"Menzel Garry E","position":1,"cik":"0001556064","reported_name":"Menzel Garry E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-06T21:54:34.000Z","date":"2024-06-06","kind":"grant","planned":false,"acquired":true,"shares":30550,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 6, 2025 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":30550,"derivative":{"exercise_price":4.65,"expiration_date":"2034-06-05","underlying":"Common Stock","underlying_shares":30550},"source":{"system":"sec-edgar","filing":"0001415889-24-015826","document":"form4-06062024_090630.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000141588924015826/form4-06062024_090630.xml","form_type":"4"}},{"id":1488470,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":34820,"kind":"person","name":"Raman Prakash","position":1,"cik":"0002018686","reported_name":"Raman Prakash","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-06T21:53:31.000Z","date":"2024-06-06","kind":"grant","planned":false,"acquired":true,"shares":30550,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 6, 2025 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":30550,"derivative":{"exercise_price":4.65,"expiration_date":"2034-06-05","underlying":"Common Stock","underlying_shares":30550},"source":{"system":"sec-edgar","filing":"0001415889-24-015823","document":"form4-06062024_090628.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000141588924015823/form4-06062024_090628.xml","form_type":"4"}},{"id":1488468,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":34817,"kind":"person","name":"Campbell Shannon","position":1,"cik":"0002018966","reported_name":"Campbell Shannon","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-06T21:52:12.000Z","date":"2024-06-06","kind":"grant","planned":false,"acquired":true,"shares":30550,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 6, 2025 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":30550,"derivative":{"exercise_price":4.65,"expiration_date":"2034-06-05","underlying":"Common Stock","underlying_shares":30550},"source":{"system":"sec-edgar","filing":"0001415889-24-015821","document":"form4-06062024_090608.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000141588924015821/form4-06062024_090608.xml","form_type":"4"}},{"id":1488467,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":34818,"kind":"person","name":"Dhingra Kapil","position":1,"cik":"0001456849","reported_name":"Dhingra Kapil","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-06T21:50:48.000Z","date":"2024-06-06","kind":"grant","planned":false,"acquired":true,"shares":30550,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 6, 2025 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":30550,"derivative":{"exercise_price":4.65,"expiration_date":"2034-06-05","underlying":"Common Stock","underlying_shares":30550},"source":{"system":"sec-edgar","filing":"0001415889-24-015819","document":"form4-06062024_090644.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000141588924015819/form4-06062024_090644.xml","form_type":"4"}},{"id":1542587,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":34817,"kind":"person","name":"Campbell Shannon","position":1,"cik":"0002018966","reported_name":"Campbell Shannon","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-04-12T21:29:32.000Z","date":"2024-04-10","kind":"grant","planned":false,"acquired":true,"shares":61100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in thirty-six (36) equal monthly installments, with the first installment vesting on May 10, 2024, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":61100,"derivative":{"exercise_price":4.98,"expiration_date":"2034-04-09","underlying":"Common Stock","underlying_shares":61100},"source":{"system":"sec-edgar","filing":"0001415889-24-010770","document":"form4-04122024_090409.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000141588924010770/form4-04122024_090409.xml","form_type":"4"}},{"id":1542586,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":34820,"kind":"person","name":"Raman Prakash","position":1,"cik":"0002018686","reported_name":"Raman Prakash","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-04-12T21:28:36.000Z","date":"2024-04-10","kind":"grant","planned":false,"acquired":true,"shares":61100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in thirty-six (36) equal monthly installments, with the first installment vesting on May 10, 2024, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":61100,"derivative":{"exercise_price":4.98,"expiration_date":"2034-04-09","underlying":"Common Stock","underlying_shares":61100},"source":{"system":"sec-edgar","filing":"0001415889-24-010769","document":"form4-04122024_090430.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000141588924010769/form4-04122024_090430.xml","form_type":"4"}},{"id":1549735,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-04T01:00:23.000Z","date":"2024-03-15","kind":"grant","planned":false,"acquired":true,"shares":3166,"price":4.54,"value":14373.64,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were issued in accordance with the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on March 14, 2024."}],"balance_after":51690,"source":{"system":"sec-edgar","filing":"0000950170-24-041554","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000095017024041554/ownership.xml","form_type":"4"}},{"id":1549734,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":17401,"kind":"person","name":"DIXON WENDY L","position":1,"cik":"0001202283","reported_name":"DIXON WENDY L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-04T00:49:49.000Z","date":"2024-03-15","kind":"grant","planned":false,"acquired":true,"shares":3253,"price":4.54,"value":14768.62,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were issued in accordance with the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on March 14, 2024."}],"balance_after":38054,"source":{"system":"sec-edgar","filing":"0001415889-24-010213","document":"form4-04042024_120440.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000141588924010213/form4-04042024_120440.xml","form_type":"4"}},{"id":1640991,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":68908,"kind":"person","name":"Hatzis-Schoch Brent","position":1,"cik":"0001637054","reported_name":"Hatzis-Schoch Brent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SEE REMARKS"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-15T22:38:54.000Z","date":"2024-02-14","kind":"grant","planned":false,"acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to this option shall vest and become exercisable on February 14, 2025, with the remainder vesting in 36 equal monthly installments thereafter."}],"balance_after":200000,"derivative":{"exercise_price":4.86,"expiration_date":"2034-02-13","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001415889-24-003969","document":"form4-02152024_100242.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000141588924003969/form4-02152024_100242.xml","form_type":"4"}},{"id":1640990,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":68907,"kind":"person","name":"Yurasov Sergey","position":1,"cik":"0001686295","reported_name":"Yurasov Sergey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-15T22:37:35.000Z","date":"2024-02-14","kind":"grant","planned":false,"acquired":true,"shares":225000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to this option shall vest and become exercisable on February 14, 2025, with the remainder vesting in 36 equal monthly installments thereafter."}],"balance_after":225000,"derivative":{"exercise_price":4.86,"expiration_date":"2034-02-13","underlying":"Common Stock","underlying_shares":225000},"source":{"system":"sec-edgar","filing":"0001415889-24-003967","document":"form4-02152024_100227.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000141588924003967/form4-02152024_100227.xml","form_type":"4"}},{"id":1640989,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-15T22:35:28.000Z","date":"2024-02-14","kind":"grant","planned":false,"acquired":true,"shares":537000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to this option shall vest and become exercisable on February 14, 2025, with the remainder vesting in 36 equal monthly installments thereafter."}],"balance_after":537000,"derivative":{"exercise_price":4.86,"expiration_date":"2034-02-13","underlying":"Common Stock","underlying_shares":537000},"source":{"system":"sec-edgar","filing":"0001415889-24-003963","document":"form4-02152024_100218.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000141588924003963/form4-02152024_100218.xml","form_type":"4"}},{"id":1641250,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":94279,"kind":"person","name":"Ni Fang","position":1,"cik":"0001895910","reported_name":"Ni Fang","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SEE REMARKS"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-15T17:45:43.000Z","date":"2024-02-14","kind":"grant","planned":false,"acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to this option shall vest and become exercisable on February 14, 2025, with the remainder vesting in 36 equal monthly installments thereafter."}],"balance_after":200000,"derivative":{"exercise_price":4.86,"expiration_date":"2034-02-13","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001415889-24-003971","document":"form4-02152024_100235.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1895910/000141588924003971/form4-02152024_100235.xml","form_type":"4"}},{"id":1641233,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":68914,"kind":"person","name":"Buck Elizabeth","position":1,"cik":"0001880385","reported_name":"Buck Elizabeth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF SCIENTIFIC OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-15T17:36:27.000Z","date":"2024-02-14","kind":"grant","planned":false,"acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to this option shall vest and become exercisable on February 14, 2025, with the remainder vesting in 36 equal monthly installments thereafter."}],"balance_after":200000,"derivative":{"exercise_price":4.86,"expiration_date":"2034-02-13","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001415889-24-003965","document":"form4-02152024_100219.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880385/000141588924003965/form4-02152024_100219.xml","form_type":"4"}},{"id":1641804,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":68944,"kind":"person","name":"Jones Erika","position":1,"cik":"0001895913","reported_name":"Jones Erika","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SEE REMARKS"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-15T17:34:08.000Z","date":"2024-02-14","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to this option shall vest and become exercisable on February 14, 2025, with the remainder vesting in 36 equal monthly installments thereafter."}],"balance_after":100000,"derivative":{"exercise_price":4.86,"expiration_date":"2034-02-13","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001415889-24-003960","document":"form4-02152024_100202.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1895913/000141588924003960/form4-02152024_100202.xml","form_type":"4"}},{"id":1709322,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-12-15T21:48:44.000Z","date":"2023-12-15","kind":"grant","planned":false,"acquired":true,"shares":4455,"price":2.73,"value":12162.15,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were issued in accordance with the Issuer's Fourth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on December 14, 2023."}],"balance_after":48524,"source":{"system":"sec-edgar","filing":"0001209191-23-058790","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000120919123058790/doc4.xml","form_type":"4"}},{"id":1709321,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":17401,"kind":"person","name":"DIXON WENDY L","position":1,"cik":"0001202283","reported_name":"DIXON WENDY L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-12-15T21:40:21.000Z","date":"2023-12-15","kind":"grant","planned":false,"acquired":true,"shares":4043,"price":2.73,"value":11037.39,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were issued in accordance with the Issuer's Fourth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on December 14, 2023."}],"balance_after":34801,"source":{"system":"sec-edgar","filing":"0001415889-23-016532","document":"form4-12152023_091215.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000141588923016532/form4-12152023_091215.xml","form_type":"4"}},{"id":1757669,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":81732,"kind":"person","name":"BIOTECH GROWTH N V","position":1,"cik":"0001259869","reported_name":"BIOTECH GROWTH N V","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":81733,"kind":"organization","name":"BB BIOTECH AG","position":2,"cik":"0000924223","reported_name":"BB BIOTECH AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-10-19T19:08:35.000Z","date":"2023-10-17","kind":"purchase","planned":false,"acquired":true,"shares":400000,"price":2.3352,"value":934080.0,"ownership":{"direct":true},"balance_after":8517839,"source":{"system":"sec-edgar","filing":"0000950170-23-054142","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/924223/000095017023054142/ownership.xml","form_type":"4"}},{"id":1778938,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-09-18T21:34:38.000Z","date":"2023-09-15","kind":"grant","planned":false,"acquired":true,"shares":3299,"price":3.6,"value":11876.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were issued in accordance with the Issuer's Fourth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on September 14, 2023."}],"balance_after":44069,"source":{"system":"sec-edgar","filing":"0001209191-23-049791","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000120919123049791/doc4.xml","form_type":"4"}},{"id":1778937,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-09-18T21:26:23.000Z","date":"2023-09-17","kind":"grant","planned":false,"acquired":true,"shares":1000000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares subject to this option shall vest and become exercisable on September 17, 2024, with the remainder vesting in 36 equal monthly installments thereafter."}],"balance_after":1000000,"derivative":{"exercise_price":3.55,"expiration_date":"2033-09-16","underlying":"Common Stock","underlying_shares":1000000},"source":{"system":"sec-edgar","filing":"0001415889-23-013339","document":"form4-09182023_090915.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000141588923013339/form4-09182023_090915.xml","form_type":"4"}},{"id":1778936,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Common Stock","published_at":"2023-09-18T21:26:23.000Z","date":"2023-09-15","kind":"grant","planned":false,"acquired":true,"shares":5208,"price":3.6,"value":18748.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were issued in accordance with the Issuer's Fourth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on September 14, 2023."}],"balance_after":46522,"source":{"system":"sec-edgar","filing":"0001415889-23-013339","document":"form4-09182023_090915.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000141588923013339/form4-09182023_090915.xml","form_type":"4"}},{"id":1778935,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":17401,"kind":"person","name":"DIXON WENDY L","position":1,"cik":"0001202283","reported_name":"DIXON WENDY L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-09-18T21:25:49.000Z","date":"2023-09-15","kind":"grant","planned":false,"acquired":true,"shares":2986,"price":3.6,"value":10749.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were issued in accordance with the Issuer's Fourth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on September 14, 2023."}],"balance_after":30758,"source":{"system":"sec-edgar","filing":"0001415889-23-013337","document":"form4-09182023_090941.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000141588923013337/form4-09182023_090941.xml","form_type":"4"}},{"id":1832936,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":19524,"kind":"organization","name":"RA CAPITAL MANAGEMENT, L.P.","position":1,"cik":"0001346824","reported_name":"RA CAPITAL MANAGEMENT, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":19525,"kind":"organization","name":"RA Capital Healthcare Fund LP","position":2,"cik":"0001315082","reported_name":"RA Capital Healthcare Fund LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":27507,"kind":"person","name":"RA Capital Nexus Fund, L.P.","position":3,"cik":"0001780117","reported_name":"RA Capital Nexus Fund, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":19526,"kind":"person","name":"Kolchinsky Peter","position":4,"cik":"0001384859","reported_name":"Kolchinsky Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":19527,"kind":"person","name":"Shah Rajeev M.","position":5,"cik":"0001619841","reported_name":"Shah Rajeev M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-07-07T20:30:27.000Z","date":"2023-07-05","kind":"purchase","planned":false,"acquired":true,"shares":935850,"price":5,"value":4679250.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Acquired from the Issuer pursuant to the public offering described in the Issuer's Prospectus filed with the Securities and Exchange Commission on June 30, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Held directly by RA Capital Healthcare Fund, L.P. (the \"Fund\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Acquired from the Issuer pursuant to the public offering described in the Issuer's Prospectus filed with the Securities and Exchange Commission on June 30, 2023."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Held directly by RA Capital Healthcare Fund, L.P. (the \"Fund\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"RA Capital Management, L.P. (the \"Adviser\") is the investment manager for the Fund and RA Capital Nexus Fund, L.P. (the \"Nexus Fund\"). The general partner of the Adviser is RA Capital Management GP, LLC (the \"Adviser GP\"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."}],"balance_after":3213828,"source":{"system":"sec-edgar","filing":"0001104659-23-079144","document":"tm2320829-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000110465923079144/tm2320829-1_4seq1.xml","form_type":"4"}},{"id":1833924,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-07-06T20:45:39.000Z","date":"2023-07-05","kind":"purchase","planned":false,"acquired":true,"shares":1000000,"price":5,"value":5000000.0,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reports the purchase of shares in the underwritten public offering of common stock of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 16 GP, LLC (\"NEA 16 GP\"), which is the sole general partner of NEA Partners 16, L.P. (\"NEA Partners 16\"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. (\"NEA 16\"), which is the direct beneficial owner of the shares. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the shares held by NEA 16 in which the Reporting Person has no pecuniary interest."}],"balance_after":4448757,"source":{"system":"sec-edgar","filing":"0001209191-23-041567","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000120919123041567/doc4.xml","form_type":"4"}},{"id":1840156,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":81732,"kind":"person","name":"BIOTECH GROWTH N V","position":1,"cik":"0001259869","reported_name":"BIOTECH GROWTH N V","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":81733,"kind":"organization","name":"BB BIOTECH AG","position":2,"cik":"0000924223","reported_name":"BB BIOTECH AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-07-03T19:36:48.000Z","date":"2023-06-30","kind":"purchase","planned":false,"acquired":true,"shares":1000000,"price":5,"value":5000000.0,"ownership":{"direct":true},"balance_after":8117839,"source":{"system":"sec-edgar","filing":"0000950170-23-031386","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/924223/000095017023031386/ownership.xml","form_type":"4"}},{"id":1842297,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":81732,"kind":"person","name":"BIOTECH GROWTH N V","position":1,"cik":"0001259869","reported_name":"BIOTECH GROWTH N V","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":81733,"kind":"organization","name":"BB BIOTECH AG","position":2,"cik":"0000924223","reported_name":"BB BIOTECH AG","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-29T17:37:02.000Z","date":"2023-06-27","kind":"purchase","planned":false,"acquired":true,"shares":1740000,"price":5.4914,"value":9555036.0,"ownership":{"direct":true},"balance_after":7117839,"source":{"system":"sec-edgar","filing":"0000899243-23-016705","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/924223/000089924323016705/doc4.xml","form_type":"4"}},{"id":1842723,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":34558,"kind":"person","name":"Epstein David M.","position":1,"cik":"0001488668","reported_name":"Epstein David M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SEE REMARKS"}}],"security":"Common Stock","published_at":"2023-06-28T20:02:20.000Z","date":"2023-06-27","kind":"sale","planned":true,"acquired":false,"shares":25000,"price":6.7,"value":167500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of December 29, 2022."}],"balance_after":671423,"source":{"system":"sec-edgar","filing":"0001415889-23-010388","document":"form4-06282023_080616.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000141588923010388/form4-06282023_080616.xml","form_type":"4"}},{"id":1852353,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-16T22:42:53.000Z","date":"2023-06-16","kind":"grant","planned":false,"acquired":true,"shares":5655,"price":2.1,"value":11875.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were issued in accordance with the Issuer's Fourth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on June 15, 2023."}],"balance_after":40770,"source":{"system":"sec-edgar","filing":"0001209191-23-038084","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000120919123038084/doc4.xml","form_type":"4"}},{"id":1852352,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":17401,"kind":"person","name":"DIXON WENDY L","position":1,"cik":"0001202283","reported_name":"DIXON WENDY L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-16T21:41:57.000Z","date":"2023-06-16","kind":"grant","planned":false,"acquired":true,"shares":5119,"price":2.1,"value":10749.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were issued in accordance with the Issuer's Fourth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on June 15, 2023."}],"balance_after":27772,"source":{"system":"sec-edgar","filing":"0001415889-23-009960","document":"form4-06162023_090654.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000141588923009960/form4-06162023_090654.xml","form_type":"4"}},{"id":1852351,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-16T21:41:19.000Z","date":"2023-06-16","kind":"grant","planned":false,"acquired":true,"shares":8929,"price":2.1,"value":18750.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were issued in accordance with the Issuer's Fourth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on June 15, 2023."}],"balance_after":41314,"source":{"system":"sec-edgar","filing":"0001415889-23-009959","document":"form4-06162023_090615.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000141588923009959/form4-06162023_090615.xml","form_type":"4"}},{"id":1889107,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-05-18T01:16:11.000Z","date":"2023-05-16","kind":"grant","planned":false,"acquired":true,"shares":16500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) May 16, 2024 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":16500,"derivative":{"exercise_price":1.82,"expiration_date":"2033-05-15","underlying":"Common Stock","underlying_shares":16500},"source":{"system":"sec-edgar","filing":"0001209191-23-030458","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000120919123030458/doc4.xml","form_type":"4"}},{"id":1889106,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":112263,"kind":"person","name":"Mayweg Alexander","position":1,"cik":"0001786260","reported_name":"Mayweg Alexander","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-18T01:11:09.000Z","date":"2023-05-16","kind":"grant","planned":false,"acquired":true,"shares":16500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) May 16, 2024 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":16500,"derivative":{"exercise_price":1.82,"expiration_date":"2033-05-15","underlying":"Common Stock","underlying_shares":16500},"source":{"system":"sec-edgar","filing":"0001415889-23-008248","document":"form4-05182023_010502.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000141588923008248/form4-05182023_010502.xml","form_type":"4"}},{"id":1889105,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":19527,"kind":"person","name":"Shah Rajeev M.","position":1,"cik":"0001619841","reported_name":"Shah Rajeev M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-18T01:10:37.000Z","date":"2023-05-16","kind":"grant","planned":false,"acquired":true,"shares":16500,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) May 16, 2024 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) May 16, 2024 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"RA Capital Management, L.P. (the \"Adviser\") is the investment manager for RA Capital Healthcare Fund, L.P. (the \"Fund\") and RA Capital Nexus Fund, L.P. (the \"Nexus Fund\").  The general partner of the Adviser is RA Capital Management GP, LLC (the \"Adviser GP\"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The option was awarded to Mr. Rajeev Shah in connection with his service as a director of the Issuer. Mr. Shah is a Managing Partner of the Adviser. and, under his arrangement with the Adviser, Mr. Shah holds the option for the benefit of the Fund and the Nexus Fund. Mr. Shah is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund and Nexus Fund to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock."}],"balance_after":16500,"derivative":{"exercise_price":1.82,"expiration_date":"2033-05-15","underlying":"Common Stock","underlying_shares":16500},"source":{"system":"sec-edgar","filing":"0001415889-23-008247","document":"form4-05182023_010525.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000141588923008247/form4-05182023_010525.xml","form_type":"4"}},{"id":1889104,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-18T01:09:34.000Z","date":"2023-05-16","kind":"grant","planned":false,"acquired":true,"shares":16500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) May 16, 2024 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":16500,"derivative":{"exercise_price":1.82,"expiration_date":"2033-05-15","underlying":"Common Stock","underlying_shares":16500},"source":{"system":"sec-edgar","filing":"0001415889-23-008246","document":"form4-05182023_010525.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000141588923008246/form4-05182023_010525.xml","form_type":"4"}},{"id":1889103,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":34819,"kind":"person","name":"Menzel Garry E","position":1,"cik":"0001556064","reported_name":"Menzel Garry E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-18T01:08:54.000Z","date":"2023-05-16","kind":"grant","planned":false,"acquired":true,"shares":16500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) May 16, 2024 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":16500,"derivative":{"exercise_price":1.82,"expiration_date":"2033-05-15","underlying":"Common Stock","underlying_shares":16500},"source":{"system":"sec-edgar","filing":"0001415889-23-008245","document":"form4-05182023_010546.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000141588923008245/form4-05182023_010546.xml","form_type":"4"}},{"id":1889102,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":34821,"kind":"person","name":"Kulkarni Samarth","position":1,"cik":"0001682019","reported_name":"Kulkarni Samarth","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-18T01:08:07.000Z","date":"2023-05-16","kind":"grant","planned":false,"acquired":true,"shares":16500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) May 16, 2024 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":16500,"derivative":{"exercise_price":1.82,"expiration_date":"2033-05-15","underlying":"Common Stock","underlying_shares":16500},"source":{"system":"sec-edgar","filing":"0001415889-23-008243","document":"form4-05182023_010501.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000141588923008243/form4-05182023_010501.xml","form_type":"4"}},{"id":1889101,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":17401,"kind":"person","name":"DIXON WENDY L","position":1,"cik":"0001202283","reported_name":"DIXON WENDY L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-18T01:07:17.000Z","date":"2023-05-16","kind":"grant","planned":false,"acquired":true,"shares":16500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) May 16, 2024 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":16500,"derivative":{"exercise_price":1.82,"expiration_date":"2033-05-15","underlying":"Common Stock","underlying_shares":16500},"source":{"system":"sec-edgar","filing":"0001415889-23-008242","document":"form4-05182023_010509.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000141588923008242/form4-05182023_010509.xml","form_type":"4"}},{"id":1889099,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":34818,"kind":"person","name":"Dhingra Kapil","position":1,"cik":"0001456849","reported_name":"Dhingra Kapil","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-18T01:06:25.000Z","date":"2023-05-16","kind":"grant","planned":false,"acquired":true,"shares":16500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) May 16, 2024 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":16500,"derivative":{"exercise_price":1.82,"expiration_date":"2033-05-15","underlying":"Common Stock","underlying_shares":16500},"source":{"system":"sec-edgar","filing":"0001415889-23-008241","document":"form4-05182023_010514.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000141588923008241/form4-05182023_010514.xml","form_type":"4"}},{"id":1944547,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-03-20T20:41:16.000Z","date":"2023-03-16","kind":"grant","planned":false,"acquired":true,"shares":7111,"price":1.67,"value":11875.37,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were issued in accordance with the Issuer's Fourth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on March 16, 2023."}],"balance_after":35115,"source":{"system":"sec-edgar","filing":"0001209191-23-020051","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000120919123020051/doc4.xml","form_type":"4"}},{"id":1944546,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":17401,"kind":"person","name":"DIXON WENDY L","position":1,"cik":"0001202283","reported_name":"DIXON WENDY L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-03-20T20:34:01.000Z","date":"2023-03-16","kind":"grant","planned":false,"acquired":true,"shares":6437,"price":1.67,"value":10749.79,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were issued in accordance with the Issuer's Fourth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on March 16, 2023."}],"balance_after":22653,"source":{"system":"sec-edgar","filing":"0001415889-23-005219","document":"form4-03202023_080355.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000141588923005219/form4-03202023_080355.xml","form_type":"4"}},{"id":1944545,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":68906,"kind":"person","name":"Velleca Mark A.","position":1,"cik":"0001706847","reported_name":"Velleca Mark A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-03-20T20:33:03.000Z","date":"2023-03-16","kind":"grant","planned":false,"acquired":true,"shares":11228,"price":1.67,"value":18750.76,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were issued in accordance with the Issuer's Fourth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on March 16, 2023."}],"balance_after":32385,"source":{"system":"sec-edgar","filing":"0001415889-23-005218","document":"form4-03202023_080357.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000141588923005218/form4-03202023_080357.xml","form_type":"4"}}],"next_cursor":"2023-03-20T20:33:03.000000Z,1944545"}